Abnormal expression of CEBPB promotes the progression of renal cell carcinoma through regulating the generation of IL-6

Abstract

Background: The CCAAT/enhancer-binding protein beta (CEBPB), a transcription factor regulating immune and inflammatory responses, has been implicated in the pathogenesis of various malignancies. However, its specific regulatory mechanism in renal cell carcinoma (RCC) remains poorly understood. Methods: The expression of CEBPB was detected in RCC cells and tissues using qRT-PCR, western blotting and immunohistochemistry. ELISA assay was used to detect the immune factors regulated by CEBPB in supernatants. Additionally, western blotting was employed to measure the phosphorylation level of STAT3 and the expression levels of its downstream target genes. Results: CEBPB was found to be overexpressed in both RCC tissues and cell lines, and its higher expression was associated with a lower survival rate. In RCC cells, CEBPB enhances the expression of IL6, consequently promoting the phosphorylation of STAT3 and the expression of its downstream target genes. This mechanism ultimately facilitates tumor progression. Conclusions: The dysregulated expression of CEBPB facilitates RCC progression through the IL6/STAT3 pathway. CEBPB is a potential diagnostic markers and a novel effective therapeutic target for RCC patients.

Keywords

• CEBPB
• Renal cell carcinoma
• IL6
• STAT3